胃肠道间质瘤药物治疗和耐药机制研究进展

Research progress on drug treatment and drug resistance mechanism of gastrointestinal stromal tumors

胃肠道间质瘤(GIST)是胃肠道最常见的间叶源性肿瘤。酪氨酸激酶抑制剂(TKI)是GIST治疗的基石,但耐药基因的突变给治疗带来了很多问题,特别是KIT耐药突变的异质性是一个主要的挑战。近年来,随着多项GIST相关药物研究的完成,揭示靶向治疗、免疫治疗、联合治疗在不同方向上治疗GIST的巨大潜力,为GIST提供更多的治疗选择。本文将从近年来的实验研究和未来方向两个方面进行综述。

Gastrointestinal stromal tumors(GIST)are the most common mesenchymal-derived tu-mors of the gastrointestinal tract.Tyrosine kinase inhibitors(TKIs)are the cornerstone of GIST thera-py,but mutations in resistance genes pose many problems for treatment,especially the heterogene-ity of KIT resistance mutations.In recent years,with the release of a number of GIST related drug research and experimental results,the great poten-tial of targeted therapy,immunotherapy and com-bination therapy to treat GIST in different direc-tions has been revealed,providing more therapeu-tic directions for GIST.This article will review the experimental research and future direction in re-cent years.